Oral Minoxidil for the Treatment of Late Alopecia in Cancer Survivors

The study evaluated the effectiveness of oral minoxidil (1.25 mg daily) in treating late alopecia in 216 female cancer survivors, primarily with a history of breast cancer, who experienced incomplete hair regrowth following chemotherapy and/or endocrine therapy. After a median of 105 days, 74% of patients showed clinical improvement in hair regrowth. Trichoscopy assessments indicated a significant increase in hair density in both frontal and occipital areas, although hair thickness did not significantly change. The treatment was well tolerated, with no patients discontinuing due to adverse effects. The study suggests oral minoxidil may be beneficial for late alopecia in this population, but further prospective, controlled studies are needed to confirm these findings.